H.C. Wainwright raised the firm’s price target on Tyra Biosciences to $17 from $15 and keeps a Buy rating on the shares. The analyst says BridgeBio’s data mitigates risk of TYRA-300 clinical development in achondroplasia. The firm increased its probability of success for TYRA-300 in achondroplasia to 35% from 30%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TYRA:
- Opco views BridgeBio data as good news for Tyra Biosciences
- Tyra Biosciences price target raised to $15 from $12 at H.C. Wainwright
- Tyra Biosciences price target raised to $25 from $17 at Oppenheimer
- Tyra Biosciences expands development of TYRA-300 into achondroplasia
- Tyra Biosciences initiated with an Outperform at Oppenheimer